TEANECK, N.J., April 9, 2021 /PRNewswire/
-- Cognizant (Nasdaq: CTSH) announced it has been named
one of the leading companies in the pharmacovigilance market,
offering an end-to-end spectrum of patient safety services in a new
report by analyst firm Everest Group. Pharmacovigilance is the
practice area aimed at ensuring drug safety through in-depth data
collection and evaluation. As part of Everest Group's
Pharmacovigilance and Complaint Management Operations – Services
PEAK Matrix® 2021, Cognizant was named a leader amongst its
peers.
Evaluating 22 pharmacovigilance and complaint management BPS
providers, Cognizant's honor was fueled by the company's immense
scale of operations, strong domain expertise and overall market
presence – with Cognizant increasing its revenue portfolio
year-over-year. This success comes as Cognizant continues to invest
in strengthening its technology-enabled solutions to better help
clients achieve their digital transformation goals. Cognizant is
also committed to creating a global network of delivery operations
centers, which provides customized support for clients and an
additional layer of business continuity.
"There is a widespread consensus in the drug/device vigilance
market that significantly increasing safety case processing volumes
is one of the most pressing challenges for enterprises," said
Manu Aggarwal, Vice President at
Everest Group. "Cognizant's strong market presence, diversified
product handling experience, exceptional scale of safety operations
and investments to enhance its technology solutions is helping
tackle the case volumes and related-challenges for its clients and
deliver cost-effective services. All these factors have contributed
to its positioning as a Leader in Everest Group's Pharmacovigilance
and Complaint Management PEAK® Matrix Assessment
2021."
"Following the unanticipated impact of the COVID-19 global
pandemic, we expect to see continuity in vaccine development and
novel drug therapies over the next several years," said Srinivas
Shankar, Senior Vice President and Global Head for Cognizant's Life
Sciences business. "Cognizant's global scale and expertise in
pharmacovigilance services, augmented by investments in automation,
AI and machine learning are helping to expedite the development of
life-saving drugs while minimizing risk to patients."
View an extract of the Everest Group PEAK Matrix
Report
Learn more about Cognizant Life Sciences Technology
Solutions
About Cognizant
Cognizant (Nasdaq-100: CTSH) is one of
the world's leading professional services companies, transforming
clients' business, operating, and technology models for the digital
era. Our unique industry-based, consultative approach helps clients
envision, build and run more innovative and efficient businesses.
Headquartered in the U.S., Cognizant is ranked 194 on the Fortune
500 and is consistently listed among the most admired companies in
the world. Learn how Cognizant helps clients lead with digital at
www.cognizant.com or follow us @Cognizant.
For further information, contact:
US:
Josh
Blumenthal
joshua.blumenthal@cognizant.com
|
Europe:
Christina
Schneider
Christina.Schneider@cognizant.com
|
Asia-Pac:
Harsh
Kabra
harsh.kabra@cognizant.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cognizant-recognized-for-its-growing-market-adoption-as-a-top-pharmacovigilance-operations-leader-in-new-everest-group-report-301265559.html
SOURCE Cognizant